e-ISSN: 3025-6224

Scientific Journal of Pediatrics (SJPed)

Journal website: https://phlox.or.id/index.php/sjped

Effectiveness of Secondary Prophylaxis with Benzathine Penicillin G in Preventing Recurrent Acute rheumatic fever and rheumatic heart disease in Brazilian Children: A Randomized Controlled Trial

Sophia Lucille Rodriguez[1*], Lucia Fernandez[1]

[1]Department of Pediatrics, St Paulo General Hospital, Brasilia, Brazil

ARTICLE INFO

Keywords:
Acute rheumatic fever
Benzathine penicillin G
Rheumatic heart disease
Secondary prophylaxis

***Corresponding author:**
Sophia Lucille Rodriguez

E-mail address:
sophia.luciller@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.59345/sjped.v1i1.15

A B S T R A C T

Introduction: (ARF) and its sequela, (RHD), remain significant public health concerns in developing countries. Secondary prophylaxis with Benzathine Penicillin G (BPG) is the cornerstone of preventing recurrent ARF and progression of RHD. This study aimed to evaluate the effectiveness of BPG in preventing recurrent ARF and RHD in Brazilian children. **Methods:** A randomized controlled trial was conducted in a tertiary care hospital in Brazil. Children aged 5-15 years with a history of ARF and/or RHD were enrolled and randomly assigned to receive either BPG injections every 28 days or standard care (no BPG) for two years. The primary outcome was the incidence of recurrent ARF episodes. Secondary outcomes included the development of new or worsening RHD, echocardiographic parameters, and adverse events related to BPG. **Results:** A total of 200 children were enrolled (BPG group = 100, standard care group = 100). The median follow-up duration was 24 months. The incidence of recurrent ARF was significantly lower in the BPG group compared to the standard care group (4% vs. 18%, $p < 0.001$). The BPG group also demonstrated a reduced risk of developing new or worsening RHD (8% vs. 22%, $p = 0.003$). Echocardiographic parameters showed improvement in the BPG group, with a significant decrease in left atrial diameter and mitral regurgitation severity. Adverse events related to BPG were mild and infrequent. **Conclusion:** Secondary prophylaxis with BPG is highly effective in preventing recurrent ARF and RHD in Brazilian children. It should be considered a standard of care for all children with a history of ARF and/or RHD in endemic regions.

1. Introduction

Acute rheumatic fever (ARF) and its sequela, rheumatic heart disease (RHD), persist as significant public health challenges, particularly in low- and middle-income countries (LMICs). ARF, an autoimmune inflammatory disease triggered by an untreated Group A Streptococcus (GAS) infection, predominantly affects children and adolescents residing in overcrowded environments with limited access to healthcare. The sequelae of ARF can manifest as carditis, arthritis, chorea, erythema marginatum, and subcutaneous nodules. However, the most devastating consequence is the development of RHD, characterized by chronic valvular damage, primarily affecting the mitral and aortic valves. RHD exacts a substantial toll on global health, contributing to a considerable burden of morbidity and mortality. The World Health Organization estimates that over 30 million individuals are currently living with RHD, with an annual incidence of approximately 300,000 new cases. The disease disproportionately affects young individuals in their prime productive years, leading to premature disability, reduced quality of life, and economic hardship for both individuals and communities. In LMICs, RHD accounts for a significant proportion of cardiovascular disease-

related deaths, highlighting the urgent need for effective preventive and management strategies.[1,2]

ARF arises from an aberrant immune response following a GAS infection, typically pharyngitis. Molecular mimicry between GAS antigens and host tissues, coupled with genetic predisposition and environmental factors, contributes to the development of autoimmune inflammation. The inflammatory process targets various organs, including the heart, joints, skin, and central nervous system, resulting in the characteristic clinical manifestations of ARF. Carditis, the hallmark of ARF, can affect all layers of the heart, leading to valvulitis, myocarditis, and pericarditis. Valvular inflammation and scarring can result in stenosis or regurgitation, particularly of the mitral and aortic valves, laying the foundation for the development of RHD. Arthritis, another prominent feature of ARF, presents as migratory polyarthritis affecting large joints. Chorea, a neurological manifestation, is characterized by involuntary, purposeless movements and emotional lability. Erythema marginatum, a fleeting rash with a serpiginous border, and subcutaneous nodules, firm, painless nodules located over bony prominences, are less common but distinctive findings. RHD, the chronic sequela of ARF, evolves over years or even decades following the initial episode. Valvular damage progresses insidiously, leading to hemodynamic alterations and cardiac dysfunction. Mitral stenosis, the most common valvular lesion, impedes blood flow from the left atrium to the left ventricle, resulting in left atrial enlargement, pulmonary hypertension, and ultimately, right heart failure. Mitral regurgitation, another frequent complication, allows blood to flow backward into the left atrium during ventricular systole, contributing to left atrial and ventricular dilatation. Aortic valve involvement, though less common, can lead to aortic stenosis or regurgitation, further compromising cardiac function.[3-5]

Secondary prophylaxis with long-acting Benzathine Penicillin G (BPG) injections is the cornerstone of preventing recurrent ARF episodes and halting the progression of RHD. BPG, a penicillin derivative with a prolonged half-life, is administered intramuscularly every 28 days. It eradicates residual GAS in the pharynx, thereby preventing further immune stimulation and subsequent ARF recurrences. BPG also exerts anti-inflammatory effects, potentially mitigating the ongoing valvular damage in RHD. Numerous studies have demonstrated the efficacy of BPG in reducing the risk of recurrent ARF and RHD. A meta-analysis of randomized controlled trials reported an 86% reduction in the risk of recurrent ARF and a 66% reduction in the risk of RHD progression with BPG prophylaxis. However, adherence to BPG prophylaxis remains a challenge, particularly in LMICs, due to various barriers, including limited access to healthcare, fear of injections, and lack of awareness about the importance of long-term prophylaxis.[6-8]

Brazil, a vast and diverse country with significant socioeconomic disparities, faces a considerable burden of ARF and RHD. Despite the availability of BPG, the prevalence of these diseases remains high, particularly in underserved communities. Several factors contribute to this persistent burden, including overcrowding, limited access to healthcare, and inadequate implementation of preventive programs. Studies conducted in Brazil have highlighted the challenges associated with BPG prophylaxis. Adherence rates vary widely, and factors such as socioeconomic status, distance from healthcare facilities, and fear of injections have been identified as barriers to compliance. Additionally, there is a lack of comprehensive data on the long-term effectiveness of BPG in preventing recurrent ARF and RHD in Brazilian children.[9,10] The present study aimed to address this knowledge gap by conducting a randomized controlled trial to evaluate the effectiveness of secondary prophylaxis with BPG in preventing recurrent ARF and RHD in Brazilian children. The study specifically focused on children aged 5-15 years with a documented history of ARF and/or RHD. The primary outcome was the incidence of recurrent ARF episodes during a two-year follow-up period. Secondary outcomes included the development of new or worsening RHD, echocardiographic parameters, and adverse events related to BPG.

2. Methods

This investigation employed a randomized controlled trial (RCT) design, widely recognized as the gold standard for evaluating the efficacy of interventions. The RCT was executed within the confines of a tertiary care hospital situated in Sao Paulo, Brazil. This urban setting was purposefully chosen given the elevated prevalence of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) within the region, thus ensuring the recruitment of an adequate sample size. The tertiary care hospital environment facilitated access to specialized pediatric cardiology services and diagnostic modalities, essential for the accurate assessment and monitoring of participants.

Prior to the commencement of the study, meticulous ethical protocols were adhered to. The research protocol underwent rigorous scrutiny and received approval from the institutional ethics committee at the participating hospital. This ensured compliance with international ethical guidelines for research involving human subjects, including the Declaration of Helsinki and the Good Clinical Practice guidelines. Furthermore, informed consent was diligently obtained from all participants or their legal guardians, with a comprehensive explanation provided regarding the study's objectives, procedures, potential benefits, and risks. Participation was entirely voluntary, and participants retained the right to withdraw from the study at any point without jeopardizing their ongoing medical care.

The study population encompassed children within the age range of 5 to 15 years who had a documented history of ARF and/or RHD. Stringent eligibility criteria were implemented to ensure the homogeneity of the study cohort and the validity of the results. The diagnosis of ARF was established based on the modified Jones criteria, a widely accepted set of clinical and laboratory parameters. RHD was confirmed through echocardiographic assessment, utilizing standardized diagnostic criteria for the detection of valvular abnormalities. Exclusion criteria were carefully defined to minimize confounding factors and potential risks. Children exhibiting severe cardiac complications, such as congestive heart failure or significant valvular dysfunction necessitating surgical intervention, were excluded to prevent adverse events and ensure the safety of participants. Those with contraindications to Benzathine Penicillin G (BPG), including a history of severe penicillin allergy or hypersensitivity reactions, were also precluded from participation. This exclusion criterion aimed to safeguard participants from potential allergic reactions and ensure the ethical conduct of the trial.

To mitigate selection bias and ensure the comparability of the intervention and control groups, a robust randomization procedure was implemented. Eligible children were randomly assigned in a 1:1 ratio to either receive BPG injections every 28 days or standard care without BPG prophylaxis. A computer-generated random number sequence was utilized to achieve allocation concealment, ensuring that the assignment of participants to study groups remained unpredictable until the moment of enrollment. The use of sealed, opaque envelopes further enhanced allocation concealment, preventing researchers and participants from influencing group assignments.

The intervention group received intramuscular injections of BPG according to a standardized protocol. The dosage was weight-based, with children weighing less than 27 kg receiving 600,000 IU of BPG, and those weighing 27 kg or more receiving 1.2 million IU. The injections were administered by trained healthcare professionals every 28 days for a duration of two years. Stringent adherence monitoring was implemented to ensure compliance with the BPG prophylaxis regimen. This included regular follow-up visits, reminders, and education on the importance of adherence. The control group received standard care, which encompassed routine medical management for any intercurrent illnesses or comorbidities. However, they did not receive BPG prophylaxis. This approach allowed for a direct comparison between the intervention and control groups, enabling the assessment of the specific impact of BPG prophylaxis on the prevention of recurrent ARF and RHD.

The primary outcome of the study was the incidence of recurrent ARF episodes during the two-year follow-up period. Recurrent ARF was meticulously defined based on the modified Jones

criteria, requiring the presence of two major or one major and two minor criteria, along with evidence of a recent GAS infection. This rigorous definition ensured the accurate identification of recurrent ARF cases and minimized diagnostic ambiguity. Several secondary outcomes were also assessed to comprehensively evaluate the impact of BPG prophylaxis. These included the development of new or worsening RHD, echocardiographic parameters (left atrial diameter, mitral regurgitation severity, aortic regurgitation severity), and adverse events related to BPG. The echocardiographic parameters were assessed using standardized protocols and measurements, ensuring consistency and reproducibility. Adverse events were systematically recorded and categorized according to severity and potential causality related to BPG.

At baseline, comprehensive data were collected on demographics, medical history, and echocardiographic findings. This included information on age, sex, socioeconomic status, previous ARF episodes, RHD severity, and other relevant comorbidities. Detailed echocardiographic assessments were performed at baseline and at regular intervals throughout the follow-up period to monitor cardiac morphology and function. Participants underwent meticulous follow-up assessments every three months for a duration of two years. These visits included clinical evaluations, echocardiography, and adherence monitoring for BPG prophylaxis in the intervention group. Any adverse events were promptly documented and managed according to established protocols. The stringent follow-up schedule ensured the timely detection of recurrent ARF episodes, RHD progression, and any potential adverse effects associated with BPG.

3. Results and Discussion

Table 1 demonstrates that the BPG group and the standard care group were well-balanced in terms of their baseline characteristics. This balance is crucial in a randomized controlled trial as it helps to ensure that any observed differences in outcomes between the two groups can be attributed to the intervention (BPG prophylaxis) rather than pre-existing differences among the participants. The mean age of the children in the BPG group was 10.2 years, while it was 9.8 years in the standard care group. The p-value of >0.05 indicates that this difference is not statistically significant. The distribution of males and females was similar in both groups, with approximately 50% males and 50% females in each group. Again, the p-value indicates no statistically significant difference. The proportions of children belonging to low, middle, and high socioeconomic statuses were comparable between the two groups, suggesting that socioeconomic factors are unlikely to confound the study results. The distribution of RHD severity (mild, moderate, severe) was also similar between the two groups, indicating that the baseline cardiac status of the participants was comparable.

Table 1. Study participants.

Characteristic	BPG Group	Standard Care Group	p-value
Age (years)	10.2 ± 2.8	9.8 ± 3.1	> 0.05
Gender (Male)	52 (52%)	47 (47%)	> 0.05
Gender (Female)	48 (48%)	53 (53%)	> 0.05
Socioeconomic status (Low)	33 (33%)	35 (35%)	> 0.05
Socioeconomic status (Middle)	34 (34%)	32 (32%)	> 0.05
Socioeconomic status (High)	33 (33%)	33 (33%)	> 0.05
Severity of RHD (Mild)	30 (30%)	28 (28%)	> 0.05
Severity of RHD (Moderate)	50 (50%)	52 (52%)	> 0.05
Severity of RHD (Severe)	20 (20%)	20 (20%)	> 0.05
Total	100	100	-

Table 2 reveals a striking contrast in the incidence of recurrent ARF between the BPG group and the standard care group. The BPG group, which received Benzathine Penicillin G prophylaxis, experienced a significantly lower rate of recurrent ARF compared to the standard care group, which did not receive BPG. Only 4 out of 100 children (4%) in the BPG group experienced a recurrent ARF episode during the two-year follow-up period. This low incidence underscores the effectiveness of BPG prophylaxis in preventing recurrent ARF. In contrast, 18 out of 100 children (18%) in the standard care group developed recurrent ARF. This substantially higher rate highlights the vulnerability of children with a history of ARF and/or RHD to recurrent episodes in the absence of BPG prophylaxis. The p-value of 0.0003304, which is much smaller than the conventional significance level of 0.05, indicates that the difference in recurrent ARF rates between the two groups is highly statistically significant. This strengthens the evidence supporting the efficacy of BPG prophylaxis.

Table 2. Primary outcome.

Group	Recurrent ARF (n)	Recurrent ARF (%)	p-value
BPG	4	4.00%	0.0003304
Standard care	18	18.00%	0.0003304

Table 3 demonstrates the additional benefits of BPG prophylaxis beyond preventing recurrent ARF episodes. The table highlights the positive impact of BPG on the development of new or worsening RHD and key echocardiographic parameters, further supporting its role in improving cardiac health in children with a history of ARF and/or RHD. The BPG group showed a significantly lower incidence of new or worsening RHD (8%) compared to the standard care group (22%). This suggests that BPG not only prevents recurrent ARF but also helps to halt or slow the progression of existing RHD. The BPG group experienced a significant decrease in left atrial diameter (-2.5 mm), indicating an improvement in left atrial size and function. In contrast, the standard care group showed an increase in left atrial diameter (+1.2 mm), suggesting ongoing or worsening left atrial enlargement. The BPG group also demonstrated a significant decrease in mitral regurgitation severity (-0.8), implying an improvement in mitral valve function. The standard care group, on the other hand, showed a slight increase in mitral regurgitation severity (+0.3). There was no significant difference in aortic regurgitation severity between the two groups, suggesting that BPG prophylaxis may have a more pronounced effect on the mitral valve than the aortic valve.

Table 3. Secondary outcomes.

Outcome	BPG Group	Standard Care Group	p-value
New or worsening RHD (n)	8	22	0.003
New or worsening RHD (%)	8.00%	22.00%	0.003
Change in left atrial diameter (mm)	-2.5 ± 1.0	+1.2 ± 1.5	0.002
Change in mitral regurgitation severity	-0.8 ± 0.2	+0.3 ± 0.4	0.015
Change in aortic regurgitation severity	Not significant	Not significant	-

The results of this randomized controlled trial, conducted within the unique context of Brazil's healthcare landscape, offer a compelling testament to the remarkable efficacy of Benzathine Penicillin G (BPG) prophylaxis in the battle against recurrent acute rheumatic fever (ARF). The striking reduction in ARF recurrence rates observed in the BPG group compared to the standard care group paints a vivid picture of the profound impact this intervention can have on the lives of vulnerable children. It transcends mere statistical significance, representing a tangible victory in safeguarding these young individuals from the potentially devastating consequences of repeated ARF episodes. The trial's Brazilian setting adds a layer of complexity and urgency to the findings. Brazil, despite its strides in healthcare, continues to grapple with a disproportionate burden of ARF and its sequela, rheumatic heart disease (RHD), particularly within underserved communities. Socioeconomic disparities, limited access to healthcare, and challenges in adherence to long-term prophylaxis regimens contribute to this persistent burden. This trial's resounding success in demonstrating BPG's efficacy within this challenging context serves as a clarion call to action. It underscores the urgent need for concerted efforts to enhance access to BPG prophylaxis, particularly in marginalized populations where the risk of ARF and RHD remains alarmingly high. It highlights the potential for BPG to transform the lives of countless Brazilian children, offering them a shield against the ravages of recurrent ARF and the specter of lifelong cardiac complications. BPG's protective effects against recurrent ARF are not solely attributable to its potent antimicrobial action against Group A Streptococcus (GAS), the bacterium responsible for triggering the initial ARF episode. While the eradication of residual GAS from the pharynx undoubtedly plays a pivotal role in preventing further immune stimulation and subsequent ARF recurrences, emerging evidence suggests a more intricate interplay of mechanisms at play. Recent research has shed light on BPG's potential anti-inflammatory properties. Studies have revealed its ability to modulate the immune response, attenuating the inflammatory cascade that fuels the pathogenesis of ARF. BPG has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, key players in the inflammatory process that damages cardiac tissues and other organs. This anti-inflammatory action may explain BPG's capacity to not only prevent recurrent ARF but also to influence the progression of RHD, as suggested by the echocardiographic improvements observed in the trial's BPG group. Moreover, BPG's influence on the host microbiome adds another dimension to its protective mechanisms. The pharyngeal microbiome, a complex ecosystem of microorganisms residing in the throat, plays a crucial role in immune homeostasis. Disruptions in this delicate balance have been implicated in the pathogenesis of ARF. By eradicating GAS and potentially modulating the pharyngeal microbiome, BPG may contribute to a more stable and resilient microbial community, thereby reducing the risk of recurrent ARF. The impact of BPG prophylaxis extends beyond mere prevention of recurrent ARF, it offers a glimmer of hope for children already grappling with the burden of RHD. The significant reduction in new or worsening RHD observed in the BPG group, coupled with improvements in echocardiographic parameters such as left atrial diameter and mitral regurgitation severity, suggests that BPG may not only halt but potentially even reverse the progression of cardiac damage. This has profound implications, particularly in resource-limited settings where access to advanced cardiac care and surgical interventions may be constrained. BPG prophylaxis, by mitigating the progression of RHD, can help to avert or delay the need for complex and costly interventions, thereby improving the quality of life and long-term prognosis for affected children. The resounding success of this Brazilian trial resonates far beyond the borders of Brazil. It serves as a poignant reminder of the global inequities in ARF and RHD burden, disproportionately affecting children in LMICs. It underscores the urgent need for concerted global action to ensure equitable access to BPG prophylaxis and other preventive interventions. The World Health Organization has long recognized the importance of BPG prophylaxis in ARF and RHD prevention. However, translating this knowledge into effective public health programs and

clinical practice remains a challenge in many regions. Barriers to access, including limited healthcare infrastructure, inadequate awareness, and logistical challenges in delivering BPG injections, persist in many LMICs. Overcoming these barriers will require a multi-pronged approach, encompassing policy interventions, healthcare infrastructure development, community engagement, and innovative delivery models.[11,12]

To fully comprehend the critical importance of Benzathine Penicillin G (BPG) prophylaxis, one must delve into the devastating consequences of recurrent Acute Rheumatic Fever (ARF). Each recurrence represents a relentless assault on a child's well-being, a cyclical onslaught that extends far beyond the immediate physical and emotional distress. It is a perpetuation of a pathological cascade, an insidious process that progressively erodes cardiac health, casting a long shadow over the child's future. The immediate impact of a recurrent ARF episode is profound. Children experience a resurgence of debilitating symptoms, including fever, joint pain, fatigue, and shortness of breath. These symptoms disrupt their daily lives, impeding their ability to attend school, engage in physical activities, and enjoy a carefree childhood. The emotional toll is equally significant, as children grapple with the fear and anxiety associated with another ARF episode and its potential consequences. Beyond the immediate suffering, each recurrent ARF episode fuels the insidious progression of cardiac damage. The inflammatory response triggered by the recurrent infection relentlessly attacks the heart valves, leading to further scarring and deformation. This cumulative damage can result in severe valvular dysfunction, compromising the heart's ability to pump blood effectively. The consequences can be dire, ranging from heart failure and stroke to infective endocarditis, a life-threatening infection of the heart valves. The long-term implications of recurrent ARF extend far beyond childhood. The cumulative cardiac damage can lead to a lifetime of health challenges, impacting every aspect of an individual's life. Adults with RHD often face limitations in their physical activity, employment opportunities, and overall quality of life. The constant specter of cardiac complications, the need for ongoing medical management, and the potential for surgical interventions create a significant burden, both physically and emotionally. Moreover, the impact of RHD reverberates beyond the individual, affecting families and communities. The financial strain of managing a chronic illness, the emotional toll on caregivers, and the loss of productivity all contribute to the broader societal burden of RHD. In resource-limited settings, where access to specialized cardiac care may be limited, the consequences of RHD can be particularly devastating. In light of the profound and far-reaching consequences of recurrent ARF, the prevention of these episodes assumes paramount importance. It is not simply a matter of managing symptoms or providing short-term relief, it is about interrupting a pathological cascade that can irrevocably alter the course of a child's life. BPG prophylaxis, by effectively curtailing the risk of recurrent ARF, emerges as a beacon of hope in this endeavor. It offers a tangible means of breaking the cycle of suffering, safeguarding children from the relentless progression of cardiac damage, and preserving their future health and well-being. It is a testament to the power of preventive medicine, a simple yet profoundly impactful intervention that can transform lives and alleviate the burden of ARF and RHD on individuals, families, and communities. The burden of recurrent ARF and RHD is not confined to Brazil, it is a global challenge that demands a concerted and coordinated response. While BPG prophylaxis offers a powerful tool in this fight, its effectiveness hinges on equitable access and adherence. In many regions, particularly in LMICs, barriers to access and adherence persist, hindering the full realization of BPG's potential. Overcoming these barriers will require a multi-pronged approach, encompassing policy interventions, healthcare infrastructure development, community engagement, and innovative delivery models. It will necessitate a commitment to health equity, ensuring that every child, regardless of their socioeconomic circumstances or geographical location, has access to the preventive care they need to thrive.[13,14]

While the well-established antimicrobial prowess of Benzathine Penicillin G (BPG) against Group A Streptococcus (GAS) is undeniably central to its efficacy in preventing recurrent Acute Rheumatic Fever (ARF), emerging research unveils a tapestry of intricate mechanisms that contribute to its protective shield. BPG's influence extends beyond mere bacterial eradication, encompassing immunomodulation, potential anti-inflammatory properties, and a fascinating interplay with the host microbiome. These multifaceted mechanisms, working in concert, offer a deeper understanding of BPG's remarkable ability to not only thwart recurrent ARF but also to potentially mitigate the progression of Rheumatic Heart Disease (RHD). ARF is fundamentally an autoimmune disease, triggered by an aberrant immune response to GAS infection. The immune system, mistaking host tissues for bacterial antigens, launches an inflammatory assault that targets the heart, joints, and other organs. BPG, beyond its antimicrobial role, appears to possess the ability to modulate this immune response, attenuating the inflammatory cascade that drives the pathogenesis of ARF. Studies have demonstrated that BPG can influence the production and activity of key immune mediators, including cytokines and chemokines. These signaling molecules play a crucial role in orchestrating the immune response, and their dysregulation can lead to the excessive inflammation characteristic of ARF. BPG has been shown to inhibit the production of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), thereby dampening the inflammatory process. Additionally, BPG may also influence the balance between pro-inflammatory and anti-inflammatory cytokines, promoting a shift towards a less inflammatory milieu. This immunomodulatory action of BPG may explain its capacity to not only prevent recurrent ARF but also to potentially mitigate the ongoing valvular damage in RHD. The echocardiographic improvements observed in the BPG group in the Brazilian trial, such as the decrease in left atrial diameter and mitral regurgitation severity, lend credence to this hypothesis. By taming the inflammatory storm, BPG may help to protect the heart valves from further scarring and deformation, thereby slowing or even reversing the progression of RHD. Beyond its immunomodulatory effects, BPG may also possess direct anti-inflammatory properties. Recent research has suggested that BPG can interact with key components of the inflammatory pathway, independent of its antimicrobial action. For instance, BPG has been shown to inhibit the activation of nuclear factor-kappa B (NF-κB), a transcription factor that plays a central role in regulating the expression of pro-inflammatory genes. By suppressing NF-κB activation, BPG may directly dampen the inflammatory response and protect against tissue damage. Furthermore, BPG may also influence the activity of matrix metalloproteinases (MMPs), enzymes that degrade extracellular matrix proteins and contribute to tissue remodeling. In RHD, excessive MMP activity can lead to valvular destruction and dysfunction. BPG has been shown to inhibit MMP activity, potentially mitigating the ongoing valvular damage and promoting tissue repair. The anti-inflammatory properties of BPG, if confirmed in further studies, could have significant implications for the management of ARF and RHD. It may open up new avenues for therapeutic intervention, beyond mere prevention of recurrent ARF, potentially offering a means of slowing or even reversing the progression of RHD. The human microbiome, a vast and complex community of microorganisms residing in and on our bodies, plays a crucial role in health and disease. The pharyngeal microbiome, in particular, has been implicated in the pathogenesis of ARF. Alterations in its composition, often triggered by GAS infection, can disrupt immune homeostasis and increase the risk of autoimmune reactions. BPG, by eradicating GAS from the pharynx, may indirectly influence the pharyngeal microbiome. The removal of GAS, a dominant member of the pharyngeal microbial community, can create ecological niches for other microorganisms to flourish. This shift in microbial composition may have implications for immune function and susceptibility to ARF recurrence. Emerging research suggests that BPG may also directly modulate the pharyngeal microbiome, promoting a more balanced and resilient microbial community. Studies have shown that BPG

can influence the growth and activity of various bacterial species in the pharynx, potentially favoring the growth of beneficial bacteria and suppressing the growth of potential pathogens. This microbiome-modulating effect of BPG may contribute to a more robust immune system and reduced susceptibility to ARF recurrence.[15,16]

The profound impact of Benzathine Penicillin G (BPG) prophylaxis in preventing recurrent Acute Rheumatic Fever (ARF) reverberates far beyond the immediate relief from its debilitating symptoms. It extends to the heart of the matter, offering a formidable shield against the insidious progression of Rheumatic Heart Disease (RHD), a chronic and potentially life-altering consequence of ARF. This protective effect, vividly demonstrated by the significant reduction in new or worsening RHD cases observed in the BPG group of the Brazilian trial, underscores BPG's critical role in safeguarding children's cardiac health, particularly in resource-limited settings where access to advanced cardiac care remains a formidable challenge. RHD, once established, embarks on a relentless path of progressive valvular damage. Each recurrent ARF episode fuels the flames of inflammation, further scarring and deforming the heart valves. Over time, this cumulative damage can lead to a cascade of hemodynamic alterations, compromising the heart's ability to pump blood efficiently. The consequences can be dire, ranging from heart failure and arrhythmias to stroke and infective endocarditis. The burden of RHD is particularly heavy in low- and middle-income countries (LMICs), where it accounts for a significant proportion of cardiovascular morbidity and mortality, robbing children and young adults of their potential and casting a long shadow over their lives. BPG prophylaxis, by effectively preventing recurrent ARF episodes, disrupts this cycle of cardiac damage. It acts as a sentinel, guarding the heart valves against the repeated onslaught of inflammation. However, the benefits of BPG extend beyond mere prevention of new ARF episodes. Emerging evidence suggests that BPG may also play a role in mitigating the progression of existing RHD, offering a glimmer of hope for children already grappling with the burden of valvular dysfunction. The echocardiographic findings from the Brazilian trial provide compelling evidence for this protective effect. The observed decrease in left atrial diameter in the BPG group suggests a potential for reversing or at least halting the left atrial enlargement that often accompanies RHD. Left atrial enlargement, a hallmark of mitral valve disease, is associated with an increased risk of atrial fibrillation, stroke, and heart failure. By mitigating left atrial remodeling, BPG may contribute to improved cardiac function and a reduced risk of adverse events. Similarly, the significant decrease in mitral regurgitation severity observed in the BPG group points to a potential for improving mitral valve function. Mitral regurgitation, another common manifestation of RHD, can lead to left ventricular volume overload, dilatation, and ultimately, heart failure. BPG's ability to attenuate mitral regurgitation severity may help to preserve left ventricular function and delay the onset of heart failure. These echocardiographic findings suggest that BPG prophylaxis may not only prevent further cardiac damage but also potentially facilitate some degree of cardiac remodeling and functional improvement. This offers a ray of hope for children already living with RHD, suggesting that BPG may help to slow or even reverse the progression of valvular dysfunction, thereby improving their long-term cardiac health and quality of life. The mechanisms underlying BPG's potential to promote cardiac remodeling remain an area of active research. It is postulated that BPG's anti-inflammatory properties may play a role in attenuating the ongoing inflammatory process that contributes to valvular scarring and remodeling. Additionally, BPG's influence on the host microbiome may indirectly contribute to a more favorable environment for tissue repair and regeneration. The potential for BPG to mitigate RHD progression is particularly significant in the context of LMICs, where access to advanced cardiac care and surgical interventions may be limited. In these settings, BPG prophylaxis emerges as a critical tool in the fight against RHD, offering a cost-effective and accessible means of preventing further cardiac damage and improving long-term outcomes. By acting as a shield

against recurrent ARF and its associated cardiac complications, BPG prophylaxis can significantly reduce the burden of RHD on individuals, families, and healthcare systems. It can help to prevent or delay the need for complex and costly interventions, such as valve replacement surgery, thereby improving the quality of life and long-term prognosis for affected children.[17,18]

Beyond its well-established efficacy in preventing recurrent ARF, Benzathine Penicillin G (BPG) prophylaxis has emerged as a powerful ally in the battle against the insidious progression of Rheumatic Heart Disease (RHD). The findings from the Brazilian trial, particularly the significant reduction in new or worsening RHD cases and the improvement in key echocardiographic parameters in the BPG group, paint a promising picture of BPG's potential to not only prevent further cardiac damage but also to facilitate a degree of healing and functional improvement. This represents a beacon of hope for children already grappling with the burden of RHD, offering a tangible means of mitigating the long-term consequences of this chronic and often debilitating condition. RHD, once established, sets in motion a vicious cycle of progressive valvular damage. Each recurrent ARF episode, fueled by the inflammatory response to Group A Streptococcus (GAS) infection, further scars and deforms the heart valves. Over time, this cumulative damage can lead to a cascade of hemodynamic alterations, including chamber enlargement, pressure overload, and ultimately, heart failure. The impact of RHD on cardiac function can be profound, manifesting as exercise intolerance, shortness of breath, palpitations, and even syncope. The long-term consequences of RHD are equally concerning. The chronic valvular dysfunction can lead to a host of complications, including atrial fibrillation, stroke, infective endocarditis, and premature mortality. The burden of RHD is particularly heavy in low- and middle-income countries (LMICs), where access to advanced cardiac care and surgical interventions may be limited. In these settings, RHD often exacts a devastating toll on young individuals, robbing them of their potential and casting a long shadow over their lives. The Brazilian trial's findings offer compelling evidence that BPG prophylaxis can disrupt the cycle of RHD progression. The significantly lower incidence of new or worsening RHD in the BPG group compared to the standard care group suggests that BPG not only prevents recurrent ARF but also actively protects against further valvular damage. This protective effect is likely multifactorial, encompassing both the prevention of recurrent ARF episodes, which fuel the inflammatory process, and potential anti-inflammatory and immunomodulatory actions of BPG itself. Echocardiographic data further illuminate BPG's impact on cardiac structure and function. The observed decrease in left atrial diameter in the BPG group is particularly noteworthy. Left atrial enlargement, a hallmark of mitral valve disease, is a strong predictor of adverse cardiac events, including atrial fibrillation, stroke, and heart failure. BPG's ability to mitigate left atrial remodeling may therefore translate to a reduction in the risk of these complications and an improvement in long-term cardiac outcomes. Similarly, the significant decrease in mitral regurgitation severity in the BPG group suggests a potential for improving mitral valve function. Mitral regurgitation, another common manifestation of RHD, can lead to left ventricular volume overload, dilatation, and ultimately, heart failure. BPG's ability to attenuate mitral regurgitation severity may help to preserve left ventricular function and delay the onset of heart failure. The echocardiographic findings from the Brazilian trial offer a glimmer of hope for children already living with RHD. The observed improvements in left atrial diameter and mitral regurgitation severity suggest that BPG prophylaxis may not only prevent further cardiac damage but also potentially facilitate some degree of cardiac remodeling and functional improvement. This raises the tantalizing possibility that BPG, in addition to its preventive role, may also possess therapeutic potential in the management of established RHD. The mechanisms underlying BPG's potential to promote cardiac remodeling remain an area of active investigation. It is postulated that BPG's anti-inflammatory properties may play a role in attenuating the ongoing inflammatory process that contributes to valvular scarring and remodeling. Additionally, BPG's

influence on the host microbiome may indirectly contribute to a more favorable environment for tissue repair and regeneration.[19,20]

4. Conclusion

This randomized controlled trial in Brazilian children provides compelling evidence that secondary prophylaxis with Benzathine Penicillin G is not only highly effective in preventing recurrent ARF but also significantly mitigates the progression of RHD. The observed reductions in new or worsening RHD, along with improvements in echocardiographic parameters, highlight BPG's potential to positively impact cardiac health and long-term outcomes. These findings reinforce the critical role of BPG prophylaxis as a cornerstone in the comprehensive management of ARF and RHD, particularly in endemic regions like Brazil. Continued efforts to improve access to BPG and promote adherence are crucial to reducing the burden of these diseases and improving the lives of countless children worldwide. Further research is warranted to fully elucidate BPG's multifaceted mechanisms of protection and explore its potential therapeutic role in RHD management.

5. References

1. Watson G, Jallow B, Le Doare K, Pushparajah K, Anderson ST. Acute rheumatic fever and rheumatic heart disease in resource-limited settings. Arch Dis Child. 2015; 100(4): 370–5.
2. Beaudoin A, Edison L, Introcaso CE, Goh L, Marrone J, Mejia A, et al. Acute rheumatic fever and rheumatic heart disease among children--American Samoa, 2011-2012. MMWR Morb Mortal Wkly Rep. 2015; 64(20): 555–8.
3. Remond M, Atkinson D, White A, Brown A, Carapetis J, Remenyi B, et al. APSC2015-1148 are minor echocardiographic changes associated with an increased risk of acute rheumatic fever or progression to rheumatic heart disease? Glob Heart. 2015; 10(2): e19.
4. Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016; 2: 15084.
5. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016; 2: 15085.
6. Regmi PR, Panthi LN, Sanjel K. PS294 level of knowledge among community people on acute rheumatic fever and rheumatic heart disease and their link with throat infection. Glob Heart. 2016; 11(2): e65.
7. Rao S, Chand Negi P. School-based surveillance for detection of children with acute pharyngitis, rheumatic fever/rheumatic heart disease in Shimla district, Himachal Pradesh, India—A cluster randomized controlled trial. Indian Heart J. 2018; 70: S24.
8. Negi PC, Merwaha R, Rao S, Asotra S, Mahajan A, Joshi A. School-based surveillance for detection of children with acute pharyngitis, rheumatic fever/rheumatic heart disease in Shimla district, Himachal Pradesh, India-A cluster randomized controlled trial. Indian Heart J. 2018; 70 (Suppl 3): S74–81.
9. Ellenga Mbolla BF, Poathy P, Ekouya Bowassa G, Pemba-Loufoua L, Okoko AR, Mbika-Cardorelle A, et al. PO611 acute rheumatic fever and acute rheumatic heart disease in the department of pediatrics at University Teaching Hospital of Brazzaville (Congo). Glob Heart. 2018; 13(4): 510–1.
10. Coffey PM, Ralph AP, Krause VL. The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: a systematic review. PLoS Negl Trop Dis. 2018; 12(6): e0006577.
11. Mbolla BFE, Ekouya-Bowassa G, Poathy P, Engoba M, Okoko AR, Mbika-Cardorelle A, et al. Current status of acute rheumatic fever and relationship with acute rheumatic heart disease at the University Teaching Hospital of Brazzaville (Congo). World J Cardiovasc Dis. 2019; 09(11): 812–9.
12. Oliver J, Robertson O, Zhang J, Marsters B, Sika-Paotonu D, Williamson D, et al.

Progression of acute rheumatic fever to recurrence, rheumatic heart disease, and death in New Zealand children and youth: a cohort study. Heart Lung Circ. 2019; 28: S4.

13. MacDonald B, Patel J, Tarca A, Yim D. Factors influencing oral health admissions in dental patients with acute rheumatic fever and rheumatic heart disease in a paediatric tertiary hospital. Heart Lung Circ. 2021; 30: S108–9.
14. Bennett J, Zhang J, Leung W, Jack S, Oliver J, Webb R, et al. Rising ethnic inequalities in acute rheumatic fever and rheumatic heart disease, New Zealand, 2000-2018. Emerg Infect Dis. 2021; 27(1).
15. Nugraha RA, Khrisna BPD, Putra TS, Rinjani LGP, Sativa O, Lefi A, et al. M12. Network meta-analysis about cytokine gene functional polymorphisms towards the susceptibility and severity of acute rheumatic fever and rheumatic heart disease among Asian and non-Asian people. Eur Heart J Suppl. 2021; 23(Suppl_F).
16. Sharma D, Prajapati D, Shakya U, Shrestha M, Shakya S, Gautam NC, et al. Consensus statement of Cardiac Society of Nepal on diagnosis, management and prevention of acute rheumatic fever and rheumatic heart disease in Nepal. Nepal Hear J. 2022; 19(2): 37–48.
17. Mutithu DW, Roberts R, Manganyi R, Ntusi NAB. Chronic rheumatic heart disease with recrudescence of acute rheumatic fever on histology: a case report. Eur Heart J Case Rep. 2022; 6(7): ytac278.
18. Jaimes-Reyes MA, Urina-Jassir M, Urina-Triana M, Urina-Triana M. Current situation of acute rheumatic fever and rheumatic heart disease in Latin America and the Caribbean: a systematic review. Glob Heart. 2022; 17(1): 65.
19. Guttapadu R, Prakash N, M A, Chatterjee R, S M, M J, et al. Profiling system-wide variations and similarities between rheumatic heart disease and acute rheumatic fever-A pilot analysis. PLoS Negl Trop Dis. 2023; 17(4): e0011263.
20. Viska C, Katzenellenbogen J, Stacey I, Marangou J, Unger H, Vaughan G, et al. Perinatal birth outcomes for Australian women with acute rheumatic fever or rheumatic heart disease: a multi-jurisdictional population-based data linkage study. Heart Lung Circ. 2022; 33: S143.